NT 222
Alternative Names: NT-222Latest Information Update: 24 Oct 2024
At a glance
- Originator NexThera
- Class Antineoplastics; Polymers; Proteins
- Mechanism of Action Adenosine deaminase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 21 Oct 2024 Early research in Solid tumours in South Korea (unspecified route), prior to October 2024 (NexThera pipeline, October 2024)